Moderna's mRNA flu vaccine is cleared for older adults as Canada allows an Ebola trial

The United States Food and Drug Administration approved Moderna's mRNA influenza vaccine for people aged 50 and older. The decision covers that age group rather than all ages. The vaccine uses mRNA technology, the same broad class of platform named in the report. The note does not list other age bands.

An approval for people 50 and older means regulators cleared use in that population. The report does not give an effectiveness percentage. It does not say when doses will reach clinics. It identifies the company, the disease target, and the age threshold.

Health Canada said it had authorized Moderna to launch a clinical trial of an mRNA Ebola vaccine aimed at the Bundibugyo strain. A trial authorization is not the same as a public vaccination campaign. It allows the study to proceed in Canada. The strain is the one already identified in the wider Ebola reporting of this period.

The flu approval and the Ebola trial permission are different regulatory acts in different countries. One concerns seasonal influenza in older adults. The other concerns an experimental Ebola vaccine entering a trial. Both name Moderna. They are not one product.

No price is given for either vaccine. No enrollment target is stated for the Canadian trial. No United States decision on the Ebola candidate is included in the flu approval. The confirmed steps are the flu clearance for ages 50 and older and the Canadian green light for the Bundibugyo trial.

The reports do not claim that either product has ended an outbreak. The Ebola item is a trial start in regulatory terms. The flu item is an approval for a defined age group. Those limits are part of what the notes actually say.